Interactions between erbitux(cetuximab) and Neupogen (filgrastim)
filgrastim and cetuximab (Moderate Drug-Drug)
ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cytotoxic chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while cytotoxic agents primarily target rapidly dividing cells.
MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after cytotoxic chemotherapy administration.
